Clinical Trials for Liver Cancer

A Phase 1 and 2 First-in-human, Open-label, Multicenter Study to Assess the Safety, Tolerability and Preliminary Efficacy of VMD-102 in Participants With Hepatocellular Carcinoma and Other Advanced Solid Tumors

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Adults with unresectable or metastatic hepatocellular carcinoma, or advanced uveal melanoma, renal cell, non-small-cell lung, or colorectal cancer after standard therapy or when standard therapy is inappropriate, receive oral VMD-102 monotherapy. VMD-102 is an investigational selective inhibitor of protein kinase C epsilon (PKCε/PRKCE).

ClinicalTrials.gov ID: NCT07636785

A Pilot Study of a DNAJB1-PRKACA Fusion Kinase Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Fibrolamellar Hepatocellular Carcinoma

Started >3 years ago

The trial was activated more than 3 years ago. This is not always bad but can indicate that the trial has less current treatments, or has had trouble getting enough patients to enroll due to other issues.

No known activity

No investigational drug(s) in this trial have shown anticancer activity yet in clinical trials

High burden on patient

The trial has a high burden on patients. An example would be a phase 1 trial with extra tumor biopsies and frequent pharmacokinetic blood draws.

TrialFetch AI summary: Eligible patients have measurable, unresectable or metastatic DNAJB1–PRKACA fusion-positive fibrolamellar hepatocellular carcinoma (age >12 years) or, if adults, other fusion-positive solid tumors. Treatment combines a peptide vaccine designed to induce T-cell responses against the fusion protein with nivolumab (anti–PD-1) and ipilimumab (anti–CTLA-4); select re-enrolling patients may receive the vaccine plus nivolumab alone.

ClinicalTrials.gov ID: NCT04248569